Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Goutières syndrome: Diagnostic and disease-monitoring implications.


Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
04 2019
Historique:
received: 20 11 2018
revised: 20 02 2019
accepted: 22 02 2019
pubmed: 4 3 2019
medline: 8 11 2019
entrez: 4 3 2019
Statut: ppublish

Résumé

Aicardi-Goutières syndrome (AGS) is a rare genetic leukoencephalopathy related to inappropriate activation of type I interferon. Neuroradiological findings are typically characterized by white matter abnormalities, cerebral atrophy and cerebral calcification. The disease usually manifests itself during the first year of life in the form of an initial "encephalitic-like" phase followed by a chronic phase of stabilization of the neurological signs. Recently new therapeutic strategies have been proposed aimed at blocking the abnormal activation of the interferon cascade. We reviewed clinical and MRI findings in three young RNASEH2B-mutated patients studied with serial CT and MRI studies. All three patients presented clinical and MRI features consistent with AGS but, very unexpectedly, an improving neuroradiological course. In patient 1, the MRI improvement was noted some months after treatment with high-dose steroid and IVIg treatment; in patients 2 and 3 it occurred spontaneously. Patient 2 did not show cerebral calcification on CT images. Our series highlights the possibility of spontaneous neuroradiological improvement in AGS2 patients, as well as the possibility of absence of cerebral calcification in AGS. The study underlines the need for extreme caution when using MRI as an outcome measure in therapeutic trials specific for this disease. MRI follow-up studies in larger series are necessary to describe the natural course of AGS.

Sections du résumé

BACKGROUND
Aicardi-Goutières syndrome (AGS) is a rare genetic leukoencephalopathy related to inappropriate activation of type I interferon. Neuroradiological findings are typically characterized by white matter abnormalities, cerebral atrophy and cerebral calcification. The disease usually manifests itself during the first year of life in the form of an initial "encephalitic-like" phase followed by a chronic phase of stabilization of the neurological signs. Recently new therapeutic strategies have been proposed aimed at blocking the abnormal activation of the interferon cascade.
MATERIALS AND METHODS
We reviewed clinical and MRI findings in three young RNASEH2B-mutated patients studied with serial CT and MRI studies.
RESULTS
All three patients presented clinical and MRI features consistent with AGS but, very unexpectedly, an improving neuroradiological course. In patient 1, the MRI improvement was noted some months after treatment with high-dose steroid and IVIg treatment; in patients 2 and 3 it occurred spontaneously. Patient 2 did not show cerebral calcification on CT images.
CONCLUSIONS
Our series highlights the possibility of spontaneous neuroradiological improvement in AGS2 patients, as well as the possibility of absence of cerebral calcification in AGS. The study underlines the need for extreme caution when using MRI as an outcome measure in therapeutic trials specific for this disease. MRI follow-up studies in larger series are necessary to describe the natural course of AGS.

Identifiants

pubmed: 30826161
pii: S1096-7192(18)30713-3
doi: 10.1016/j.ymgme.2019.02.006
pii:
doi:

Substances chimiques

ribonuclease HII EC 3.1.26.-
Ribonuclease H EC 3.1.26.4

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

489-494

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Davide Tonduti (D)

Pediatric Neurology Unit, V. Buzzi Children's Hospital, Milan, Italy. Electronic address: davide.tonduti@asst-fbf-sacco.it.

Giana Izzo (G)

Department of Pediatric Radiology and Neuroradiology, V. Buzzi Children's Hospital, Milan, Italy.

Stefano D'Arrigo (S)

Child Neurology Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Daria Riva (D)

Child Neurology Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Isabella Moroni (I)

Child Neurology Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Giovanna Zorzi (G)

Child Neurology Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Vanessa Cavallera (V)

Child and Adolescent Neurology Department, IRCCS Mondino Foundation, Pavia, Italy.

Anna Pichiecchio (A)

Neuroradiology Unit, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.

Carla Uggetti (C)

Neuroradiology Unit, Department of Radiology, ASST Santi Paolo e Carlo, San Carlo Borromeo Hospital, Milan, Italy.

Pierangelo Veggiotti (P)

Pediatric Neurology Unit, V. Buzzi Children's Hospital, Milan, Italy; Biomedical and Clinical Science Department, University of Milan, Milan, Italy.

Simona Orcesi (S)

Child and Adolescent Neurology Department, IRCCS Mondino Foundation, Pavia, Italy.

Luisa Chiapparini (L)

Neuroradiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Cecilia Parazzini (C)

Department of Pediatric Radiology and Neuroradiology, V. Buzzi Children's Hospital, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH